Hope therapeutics, inc. and nrx pharmaceuticals, inc. (nasdaq:nrxp) announce potential acquisition and financing agreements for $30 million in currently-operating interventional psychiatry clinics

$30 million term sheet from qualified lender for non-dilutive financing for first clinic acquisitions; anticipated closing within 60 days executed non-binding term sheet with initial clinic partners generating annual revenue of over $10 million, with additional partners to be selected under this initial funding agreement company projects annualized revenues of $100 million through continued acquisition by mid 2025 additional information to be presented at upcoming hc wainwright annual global investment conference in new york, september 9-11, 2024 miami , aug. 26, 2024 /prnewswire/ -- hope therapeutics, inc., a wholly-owned subsidiary of nrx pharmaceuticals, inc. (nasdaq: nrxp) ("hope," the "company"), a medical and technology driven company, today announced signing a non-binding term sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a term sheet for five currently operational clinics in the western united states. in addition to the currently-signed non-binding term sheet, the company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million.
NRXP Ratings Summary
NRXP Quant Ranking